MOLECULAR MEDICINE of SPHINGOLIPIDS

Until the late 1980s, sphingolipids were believed to represent structural components of the plasma membrane, whose function was to provide a protective barrier to the cell. Sphingolipids are now recognized signals for fundamental cellular processes, such as proliferation, survival, cell death, adhesion, migration, angiogenesis, and embryogenesis.



The explosion of knowledge regarding sphingolipids was facilitated by biochemical studies of their signaling properties (in particular, ceramide and sphingosine-1-phosphate), the cloning of enzymes of sphingolipid metabolism, development of genetic models for determining their physiologic roles, and the establishment of biochemical, biophysical, and optical methods for their detection and quantitation.



mouseover thumbnails above for larger view



The next step in the evolution of sphingolipids will be the transfer of basic insights into the biochemistry and cell biology of human disease. The recent success of the sphingolipid drug, Fingolimod, a sphingosine 1-phosphate agonist, which rapidly became first line therapy for multiple sclerosis, exemplifies the potential of targeting sphingolipids for treatment of human disorders.



The aim of this EMBO MOLECULAR MEDICINE WORKSHOP on SPHINGOLIPIDS is to serve as a forum where basic researchers in collaboration with the pharmaceutical industry define the next stage of pre-clinical and clinical development of this fascinating class of lipids named for the secrets of the Sphinx.



The aim of the meeting series will be to bring together basic scientists, pharmacologists and clinicians to define the role of sphingolipids in human diseases and to develop novel treatments. The meeting series will be instrumental in translating basic science knowledge about cellular regulation and functions of sphingolipids into novel therapeutic strategies and regimens. In this regard, the meeting series will focus on the role of sphingolipids in infectious diseases, malignant tumors, neurobiology and neuro-psychiatric disorders, cardio-reno-vascular disorders, development and regeneration, skin diseases, immunity and auto-iimmune disorders.

+ show speakers and program
Kathy


Banner


Novartis Pharmaceuticals UK Limited


UK




Tamar


Ben-Yosef


Technion, Israel Institute of Technology


IL




Andreas


Billich


Novartis Inst for BioMedical Research


CH




Julia


Busik


Michigan State University


US




Marie-Thérèse


Dimanche-Boitrel


Université Rennes


FR




Annette


Draeger


University of Bern


CH




Zvi


Fuks


Memorial Sloan-Kettering Cancer Center


US




Carmen


Garcia Ruiz


Spanish National Research Council


ES




Yusuf A.


Hannun


Medical University of South Carolina


US




Brian


Henry


University of Duisburg-Essen


DE




Timonthy


Hla


Cornell University


US




Thorsten


Horneman


University Hospital Zürich


CH




Mark


Kester


Penn State University College of Medicine


US




Johannes


Kornhuber


University of Erlangen-Nuremberg


DE




Thierry


Levade


INSERM UMR1037


FR




Lina M.


Obeid


Medical University of South Carolina


US




Besim


Ogretmen


Medical University of South Carolina


US




Cristiana


Perrotta


University of Milan


IT




Irina


Petrache


Indiana University


US




Yael


Pewzner-Jung


Weizmann Institute of Science


IL




Josef


Pfeilschifter


Goethe Universitat


DE




Fran


Platt


University of Oxford


UK




Susan


Pyne


University of Strathclyde


UK




Jim


Rotolo


Ceramide Therapeutics LLC


US




Sybille


Schneider-Schaulies


University of Würzburg


DE





Edward H.


Schuchman


Mount Sinai School of Medicine


US




Mitsutoshi


Setou


Hamamatsu University School of Medicine


JP




Walter A.


Shaw


Avanti Polar Lipids, Inc.,


US




Sarah


Spiegel


VCU Medical Center


US




Catharina


Svanborg


Lund University


SE




Charles


Swanton


Cancer Research UK


UK




Stefan


Uhlig


RWTH Aachen University


DE




Silke


Walter


University Hospital of the Saarland


DE


16 Oct - 21 Oct 2012
Sea of Galilee
Israel
meeting website